OR WAIT null SECS
June 06, 2024
An analysis of the general medicine portion of the pharmacy market amid ensuing challenges.
May 31, 2024
Financial commitment will go toward expanding the CDMO’s integrated antibody-drug conjugate services.
May 24, 2024
The deal grows it pipeline, powered by panCAR programs in autoimmune disease and oncology.
With the acquisition, Merck’s US and Canada life science business aims to further increase its viral vector manufacturing capabilities.
May 23, 2024
The deal features felzartamab, an investigational anti-CD38 monoclonal antibody, whose clinical outcomes have shown potential to tackle various immune-mediated diseases.
May 21, 2024
The agreement is expected to focus on cell manufacturing processes, with potential for sharing tech with academia, startups.
May 20, 2024
The facility, company says, will be its first that covers end-to-end ADC production.
The company increases its selection of atopic dermatitis treatments in the process.
May 17, 2024
Leaders in the space discuss aspects of experimental drug support and more at this year’s US Pharma and Biotech Summit.
May 13, 2024
A cohort study investigates how the use of a murine chimeric monoclonal antibody biosimilar—as opposed to the original biological drug—affects healthcare expenditures.